MGMT and glioblastoma: Furthermore, the already-discussed applications of AI in genomics have facilitated the identification of survival-related molecular markers, inducing—but not limited to—IDH mutation, CDKN2A alteration, and MGMT promoter methylation status [163,164], as CNNs trained on histopathological slides have demonstrated their capacity to predict GBM prognosis with high accuracy (over 85%) [165].